Attention Deficit Hyperactivity Disorder (ADHD) Treatments
Find Attention Deficit Hyperactivity Disorder (ADHD) Treatments
Generic Name
Lisdexamfetamine Dimesylate
Brand Names
Vyvanse, Arynta
FDA approval date: February 23, 2007
Classification: Central Nervous System Stimulant
Form: Tablet, Capsule, Solution
What is Vyvanse (Lisdexamfetamine Dimesylate)?
Lisdexamfetamine Dimesylate Capsules are indicated for the treatment of: Attention Deficit Hyperactivity Disorder in adults and pediatric patients 6 years and older [see Clinical Studies (1.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Tired of the same old research?
Related Clinical Trials
A Phase 1, Single Blind, Parallel-arm Trial to Assess the Potential for Pharmacodynamic Interaction of Centanafadine When Co-administered With Stimulants in Healthy Adults
Summary: This study will look at how centanafadine works when taken together with stimulant medicines in healthy adults, and whether combining them affects how the body responds.
Exploring Feasibility and Acceptability of Prolonged Administration of High-Dose Stimulants in People With Methamphetamine Use Disorder: An Extension of a Randomized, Placebo-Controlled Trial
Summary: Methamphetamine use disorder (MUD) is becoming an increasing public health concern in Canada. While the evidence on the efficacy and safety of prescription psychostimulants for the treatment of MUD is promising, the knowledge on the maintenance therapy using stimulant agonist therapy is scarce and needs further investigation, especially in terms of long-term retention in treatment. The goal of thi...
Addition of High Dose Stimulant and Engagement-focused Contingency Management (CM), Alone and in Combination, to Treatment as Usual (TAU) for the Management of Methamphetamine (MA) Use Disorder (ASCME): a Canadian Multi-centre, RCT
Summary: The goal of this clinical trial is to learn if administering a high dose stimulant with Contingency Management reduces days of use in adults who use methamphetamine better than the usual treatment provided by the clinic. The main questions the trial aims to answer are: Is a high dose stimulant better than a placebo and usual treatment at helping reduce the number of days they use methamphetamine? ...
Related Latest Advances
Brand Information
Vyvanse (lisdexamfetamine dimesylate)
WARNING: ABUSE, MISUSE, AND ADDICTION
VYVANSE has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including VYVANSE, can result in overdose and death
Before prescribing VYVANSE, assess each patient's risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout VYVANSE treatment, reassess each patient's risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction
1INDICATIONS AND USAGE
VYVANSE
- Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older
- Moderate to severe binge eating disorder (BED) in adults
2CONTRAINDICATIONS
VYVANSE is contraindicated in patients with:
- Known hypersensitivity to amphetamine products or other ingredients of VYVANSE. Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have been observed in postmarketing reports
- Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis
3ADVERSE REACTIONS
The following adverse reactions are discussed in greater detail in other sections of the labeling:
- Known hypersensitivity to amphetamine products or other ingredients of VYVANSE
- Hypertensive Crisis When Used Concomitantly with Monoamine Oxidase Inhibitors
- Abuse, Misuse, and Addiction
- Risks to Patients with Serious Cardiac Disease
- Increased Blood Pressure and Heart Rate
- Psychiatric Adverse Reactions
- Long-Term Suppression of Growth in Pediatric Patients
- Peripheral Vasculopathy, including Raynaud's phenomenon
- Serotonin Syndrome
- Motor and Verbal Tics, and Worsening of Tourette's Syndrome
3.1Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
3.2Postmarketing Experience
The following adverse reactions have been identified during post-approval use of VYVANSE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events are as follows: cardiomyopathy, mydriasis, diplopia, difficulties with visual accommodation, blurred vision, eosinophilic hepatitis, anaphylactic reaction, hypersensitivity, dyskinesia, dysgeusia, motor and verbal tics, bruxism, depression, dermatillomania, alopecia, aggression, Stevens-Johnson Syndrome, chest pain, angioedema, urticaria, seizures, libido changes, frequent or prolonged erections, constipation, rhabdomyolysis, and intestinal ischemia.
4DESCRIPTION
VYVANSE (lisdexamfetamine dimesylate), a CNS stimulant, is for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-
Lisdexamfetamine dimesylate is a white to off-white powder that is soluble in water (792 mg/mL).
5PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
6PRINCIPAL DISPLAY PANEL - 10 mg Capsule Bottle Label
NDC 59417-101-10
Vyvanse®
(lisdexamfetamine
(lisdexamfetamine
10 mg
CII
100 CAPSULES
Takeda
7PRINCIPAL DISPLAY PANEL - 20 mg Capsule Bottle Label
NDC 59417-102-10
Vyvanse®
(lisdexamfetamine
(lisdexamfetamine
20 mg
CII
100 CAPSULES
Takeda
8PRINCIPAL DISPLAY PANEL - 30 mg Capsule Bottle Label
NDC 59417-103-10
Vyvanse®
(lisdexamfetamine
(lisdexamfetamine
30 mg
CII
100 CAPSULES
Takeda
9PRINCIPAL DISPLAY PANEL - 40 mg Capsule Bottle Label
NDC 59417-104-10
Vyvanse®
(lisdexamfetamine
(lisdexamfetamine
40 mg
CII
100 CAPSULES
Takeda
10PRINCIPAL DISPLAY PANEL - 50 mg Capsule Bottle Label
NDC 59417-105-10
Vyvanse®
(lisdexamfetamine
(lisdexamfetamine
50 mg
CII
100 CAPSULES
Takeda
11PRINCIPAL DISPLAY PANEL - 60 mg Capsule Bottle Label
NDC 59417-106-10
Vyvanse®
(lisdexamfetamine
(lisdexamfetamine
60 mg
CII
100 CAPSULES
Takeda
12PRINCIPAL DISPLAY PANEL - 70 mg Capsule Bottle Label
NDC 59417-107-10
Vyvanse®
(lisdexamfetamine
(lisdexamfetamine
70 mg
CII
100 CAPSULES
Takeda
13PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label
NDC 59417-115-01
Vyvanse®
(lisdexamfetamine
(lisdexamfetamine
10 mg
100 CHEWABLE
Chew tablets completely Do
not swallow tablets whole.
not swallow tablets whole.
CII
Takeda
14PRINCIPAL DISPLAY PANEL - 20 mg Tablet Bottle Label
NDC 59417-116-01
Vyvanse®
(lisdexamfetamine
(lisdexamfetamine
20 mg
100 CHEWABLE
Chew tablets completely Do
not swallow tablets whole.
not swallow tablets whole.
CII
Takeda
15PRINCIPAL DISPLAY PANEL - 30 mg Tablet Bottle Label
NDC 59417-117-01
Vyvanse®
(lisdexamfetamine
(lisdexamfetamine
30 mg
100 CHEWABLE
Chew tablets completely Do
not swallow tablets whole.
not swallow tablets whole.
CII
Takeda
16PRINCIPAL DISPLAY PANEL - 40 mg Tablet Bottle Label
NDC 59417-118-01
Vyvanse®
(lisdexamfetamine
(lisdexamfetamine
40 mg
100 CHEWABLE
Chew tablets completely Do
not swallow tablets whole.
not swallow tablets whole.
CII
Takeda
17PRINCIPAL DISPLAY PANEL - 50 mg Tablet Bottle Label
NDC 59417-119-01
Vyvanse®
(lisdexamfetamine
(lisdexamfetamine
50 mg
100 CHEWABLE
Chew tablets completely Do
not swallow tablets whole.
not swallow tablets whole.
CII
Takeda
18PRINCIPAL DISPLAY PANEL - 60 mg Tablet Bottle Label
NDC 59417-120-01
Vyvanse®
(lisdexamfetamine
(lisdexamfetamine
60 mg
100 CHEWABLE
Chew tablets completely Do
not swallow tablets whole.
not swallow tablets whole.
CII
Takeda
